Next Article in Journal
Placental Inflammation in Preterm Premature Rupture of Membranes and Risk of Neurodevelopmental Disorders
Previous Article in Journal
CK2α Deletion in the Hematopoietic Compartment Shows a Mild Alteration in Terminally Differentiated Cells and the Expansion of Stem Cells
Previous Article in Special Issue
CD6 in Human Disease
 
 
Article
Peer-Review Record

Insulin Predicts Methotrexate Response by Affecting the Transcription of Methotrexate Target Genes in the Treatment-Naive Rheumatoid Arthritis

Cells 2025, 14(13), 964; https://doi.org/10.3390/cells14130964
by Victoria M. E. Lundgren 1, Malin C. Erlandsson 1,2, Venkataragavan Chandrasekaran 1, Sofia Töyrä Silfverswärd 3, Rille Pullerits 1,4 and Maria I. Bokarewa 1,2,*
Reviewer 1:
Reviewer 2: Anonymous
Cells 2025, 14(13), 964; https://doi.org/10.3390/cells14130964
Submission received: 14 May 2025 / Revised: 13 June 2025 / Accepted: 20 June 2025 / Published: 24 June 2025
(This article belongs to the Special Issue Molecular Mechanisms and Therapeutic Targets of Autoimmune Diseases)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

There is no clinically useful model to predict responsiveness to methotrexate treatment in RA. Thus, this work aimed to build a prediction model that is easy to apply in a clinical setting.

This model is based on measuring insulin levels and INFg production in patients' sera, combined with other factors such as age, and the classification score of the disease, and these together can predict MTX responsiveness of early RA patients. They suggest that insulin modulates the transcription of MTX target genes, and this could facilitate the response to MTX.

This is a nice piece of work, and applying this model will shorten the time till a patient can get the right therapy. 

 

 

Author Response

Please see attached file

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors
  • I assume the authors adopted 2010 ACR/EULAR classification criteria for diagnosis of RA, which is not clearly stated in Materials and methods section. It is not clear for me how the patients in Supplementary Table S1 with ‘RA classification score’ being less than 6 were included in the study cohorts. Were the patients described in Subsection 2.1. diagnosed based on 2010 ACR/EULAR classification criteria or patients diagnosed by attending physicians’ own decision included? Or patients diagnosed on 1987 ARA criteria even included?
  • Exclusion criteria: concomitant rheumatic diseases might affect joint manifestations and cytokine profiles. Were the patients with concomitant rheumatic diseases such as secondary Sjögren’s syndrome included or excluded?
  • Line 437: Do the authors think the findings would be applicable to inflammatory arthritis other than RA?

Author Response

Please see attached file

 

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

Comments and Suggestions for Authors

(No further comments)

Back to TopTop